XML 386 R59.htm IDEA: XBRL DOCUMENT
v3.26.1

Revenue (Details) - EUR (€) € in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2025 | Dec. 31, 2024 | Dec. 31, 2023
Revenue |  |  |
Revenue from contracts with customers | € 777,079 | € 782,517 | € 772,009
Revenue from contributions | 11,294 | 14,450 | 9,417
Total revenue | 788,373 | 796,967 | 781,426
At a point in time |  |  |
Revenue |  |  |
Revenue from contracts with customers | 164,152 | 127,280 | 88,587
Over a period of time |  |  |
Revenue |  |  |
Revenue from contracts with customers | 612,927 | 655,237 | 683,421
Fee for service and FTE-based research services |  |  |
Revenue |  |  |
Revenue from contracts with customers | 612,927 | 737,394 | 726,929
Material re-charges to customers |  |  |
Revenue |  |  |
Revenue from contracts with customers | 31,892 | 38,578 | 37,561
Milestone fees |  |  |
Revenue |  |  |
Revenue from contracts with customers | 9,615 | 2,871 | 4,785
Licences |  |  |
Revenue |  |  |
Revenue from contracts with customers | 122,345 | 3,130 | 675
Other fees |  |  |
Revenue |  |  |
Revenue from contracts with customers | 300 | 544 | 2,059
Discovery & Preclinical Development |  |  |
Revenue |  |  |
Revenue from contracts with customers | 517,636 | 599,086 | 664,516
Revenue from contributions | 11,294 | 12,308 | 8,461
Total revenue | 528,930 | 611,394 | 672,977
Discovery & Preclinical Development | At a point in time |  |  |
Revenue |  |  |
Revenue from contracts with customers | 49,121 | 83,157 | 42,345
Discovery & Preclinical Development | Over a period of time |  |  |
Revenue |  |  |
Revenue from contracts with customers | 468,515 | 515,929 | 622,171
Discovery & Preclinical Development | Fee for service and FTE-based research services |  |  |
Revenue |  |  |
Revenue from contracts with customers | 468,515 | 553,963 | 619,437
Discovery & Preclinical Development | Material re-charges to customers |  |  |
Revenue |  |  |
Revenue from contracts with customers | 31,892 | 38,578 | 37,561
Discovery & Preclinical Development | Milestone fees |  |  |
Revenue |  |  |
Revenue from contracts with customers | 9,615 | 2,871 | 4,785
Discovery & Preclinical Development | Licences |  |  |
Revenue |  |  |
Revenue from contracts with customers | 7,314 | 3,130 | 674
Discovery & Preclinical Development | Other fees |  |  |
Revenue |  |  |
Revenue from contracts with customers | 300 | 544 | 2,059
Just - Evotec Biologics |  |  |
Revenue |  |  |
Revenue from contracts with customers | 259,443 | 183,431 | 107,493
Revenue from contributions |  | 2,142 | 956
Total revenue | 259,443 | 185,573 | 108,449
Just - Evotec Biologics | At a point in time |  |  |
Revenue |  |  |
Revenue from contracts with customers | 115,031 | 44,123 | 46,242
Just - Evotec Biologics | Over a period of time |  |  |
Revenue |  |  |
Revenue from contracts with customers | 144,412 | 139,308 | 61,251
Just - Evotec Biologics | Fee for service and FTE-based research services |  |  |
Revenue |  |  |
Revenue from contracts with customers | 144,412 | € 183,431 | 107,492
Just - Evotec Biologics | Licences |  |  |
Revenue |  |  |
Revenue from contracts with customers | € 115,031 |  | € 1

X
- Definition Revenue from contributions + References No definition available. + Details
Name: | evo_RevenueFromContributions
Namespace Prefix: | evo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2025-01-01 -Paragraph 28 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2025-01-01 -Paragraph 23 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2025-01-01 -Paragraph 32 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard -URIDate 2025-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2025-01-01 -Paragraph 33 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard -URIDate 2025-03-27 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2025-01-01 -Paragraph 34 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard -URIDate 2025-03-27 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2025-01-01 -Paragraph 33 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard -URIDate 2025-03-27 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph B12 -Subparagraph b -Clause v -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B -URIDate 2025-03-27 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph B10 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B -URIDate 2025-03-27 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Note Expiry date 2027-01-01 -Name IAS -Number 1 -IssueDate 2025-01-01 -Paragraph 82 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard -URIDate 2025-03-27 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Note Expiry date 2027-01-01 -Name IAS -Number 1 -IssueDate 2025-01-01 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard -URIDate 2025-03-27 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Note Expiry date 2027-01-01 -Name IAS -Number 1 -IssueDate 2025-01-01 -Paragraph 102 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_Revenue
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2025-01-01 -Paragraph 114 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2025-01-01 -Paragraph 113 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard -URIDate 2025-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=evo_ServiceFeesAndFteBasedResearchPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=evo_RechargesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=evo_MilestoneFeesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=ifrs-full_LicencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=evo_OtherFeesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=evo_SharedRDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=evo_JustEvotecBiologicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |